Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Der Nervenarzt
Erschienen in:

12.08.2024 | Störungen durch Cannabis | Leitthema

Cannabiskonsum und Cannabiskonsumstörungen

verfasst von: Prof. Dr. E. Hoch, Prof. Dr. med. U. W. Preuss

Erschienen in: Der Nervenarzt | Ausgabe 9/2024

Einloggen, um Zugang zu erhalten

Zusammenfassung

Cannabiskonsum und Cannabiskonsumstörungen haben durch die Teillegalisierung eine neue gesellschaftliche Brisanz erreicht. Im Jahr 2021 nutzten 4,5 Mio. Erwachsene (8,8 %) in Deutschland die Droge. Die Zahl der Konsumenten und Konsumentinnen wie auch des problematischen Konsums ist angestiegen. Cannabisprodukte mit hohem δ‑9-Tetrahydrocannabinol(THC)-Gehalt sowie deren regelmäßiger Konsum führen zu Änderungen der Cannabinoidrezeptorverteilung im Gehirn und zu Modifikationen der Struktur und Funktionsfähigkeit relevanter neuronaler Netzwerke. Folgen des Konsums von Cannabinoiden liegen vor allem im psychischen Bereich und können Intoxikationen, schädlicher Gebrauch, Abhängigkeit mit Entzugssymptomen und cannabisinduzierte psychische Störungen sein. Änderungen der Diagnostik zwischen International Statistical Classification of Diseases and Related Health Problems 10 (ICD-10) und ICD-11 werden dargestellt. Eine interdisziplinäre S3-Leitinie „Cannabisbezogene Störungen“ wird aktuell entwickelt und in Kürze fertiggestellt.
Literatur
1.
Anthony JC, Warner LA, Kessler RC (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol 2:244–268CrossRef
2.
Arnaud N, Wartberg L, Simon-Kutscher K, Thomasius R (2024) IMAC-Mind Consortium. Prevalence of substance use disorders and associations with mindfulness, impulsive personality traits and psychopathological symptoms in a representative sample of adolescents in Germany. Eur Child Adolesc Psychiatry 33(2):451–465 (Feb)PubMedCrossRef
3.
Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP (2020) Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: a systematic review and meta-analysis. JAMA Netw Open 3:e202370PubMedPubMedCentralCrossRef
4.
Bara A, Ferland JN, Rompala G et al (2021) Cannabis and synaptic reprogramming of the developing brain. Nat Rev Neurosci 22:423–438PubMedPubMedCentralCrossRef
5.
Battistella G, Fornari E, Annoni JM et al (2014) Long-term effects of cannabis on brain structure. Neuropsychopharmacology 39:2041–2048PubMedPubMedCentralCrossRef
6.
Bayraktar G, Kreutz MR et al (2018) Neuronal DNA methyltransferases: epigenetic mediators between synaptic activity and gene expression? Neuroscientist 24:171–185PubMedCrossRef
7.
Blanco-Hinojo L, Pujol J, Harrison BJ et al (2017) Attenuated frontal and sensory inputs to the basal ganglia in cannabis users. Addict Biol 22:1036–1047PubMedCrossRef
8.
Blest-Hopley G, Colizzi M, Giampietro V et al (2020) Is the adolescent brain at greater vulnerability to the effects of cannabis? A narrative review of the evidence. Front Psychiatry 11:859PubMedPubMedCentralCrossRef
9.
Bolla KI, Eldreth DA, Matochik JA et al (2005) Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 26:480–492PubMedCrossRef
10.
Buckley NE, Hansson S, Harta G et al (1998) Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 82:1131–1149PubMedCrossRef
11.
Calabria B, Degenhardt L, Briegleb C et al (2010) Systematic reviews of prospective studies investigating “remission” from amphetamine, cannabis, cocaine and opioid dependence. Addict Behav 35:741–749PubMedCrossRef
12.
Chang L, Yakupov R, Cloak C et al (2006) Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 129:1096–1112PubMedCrossRef
13.
Broyd SJ, van Hell HH, Beale C et al (2016) Acute and chronic effects of cannabinoids on human cognition—a systematic review. Biol Psychiatry 79:557–567PubMedCrossRef
14.
15.
Cheetham A, Allen NB, Whittle S et al (2012) Orbitofrontal volumes in early adolescence predict initiation of cannabis use: a 4-year longitudinal and prospective study. Biol Psychiatry 71:684–692PubMedCrossRef
16.
Chung T, Cornelius J, Clark D, Martin C (2017) Greater prevalence of proposed ICD-11 alcohol and cannabis dependence compared to ICD-10, DSM-IV, and DSM‑5 in treated adolescents. Alcohol Clin Exp Res 41(9):1584–1592PubMedPubMedCentralCrossRef
17.
Chye Y, Solowij N, Suo C et al (2017b) Cannabis-related hippocampal volumetric abnormalities specific to subregions in dependent users. Psychopharmacology 234:2149–2157 (Berl)PubMedCrossRef
18.
Chye Y, Solowij N, Ganella EP et al (2017a) Orbitofrontal and caudate volumes in cannabis users: a multi-site mega-analysis comparing dependent versus non-dependent users. Psychopharmacology 234:1985–1995PubMedCrossRef
19.
20.
Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD (2022) Clinical management of cannabis withdrawal. Addiction 117(7):2075–2095PubMedPubMedCentralCrossRef
21.
Cousijn J, Wiers RW, Ridderinkhof KR et al (2012) Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage 59:3845–3851PubMedCrossRef
22.
D’Addario C, Di Francesco A, Pucci M et al (2013) Epigenetic mechanisms and endocannabinoid signaling. FEBS J 280:1905–1917PubMedCrossRef
23.
Degenhardt L, Bharat C, Bruno R, Glantz MD, Sampson NA, Lago L, WHO World Mental Health Survey Collaborators (2019) Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO’s World Mental Health Surveys. Addiction 114(3):534–552PubMedCrossRef
24.
25.
Falkai P, Wittchen H‑U (Hrsg) (2015) Diagnostisches und statistisches Manual psychischer Störungen DSM Bd. 5. Hogrefe, S 26–27
26.
27.
Gossop M, Darke S, Griffiths P et al (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90(5):607–614PubMedCrossRef
28.
29.
Guttman Z, Moeller SJ, London ED (2018) Neural underpinnings of maladaptive decision-making in addictions. Pharmacol Biochem Behav 164:84–98PubMedCrossRef
30.
Hazekamp A, Bastola K, Rashidi H et al (2007) Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol 113:85–90PubMedCrossRef
31.
32.
Hoch E, Olderbak S, Schwarzkopf L, Gomes de Matos E, Schneider F (2024) Cannabis – Zahlen und Fakten. In: Deutsche Hauptstelle für Suchtfragen (Hrsg) DHS Jahrbuch Sucht. Pabst, Lengerich
33.
Hoch E, Petersen K, Thomasius R (2022) Cannabis. In: Batra A, Bilke-Hentsch O (Hrsg) Praxisbuch Sucht. Thieme, Stuttgart
34.
Hoch E, Friemel C, Schneider M (2019) Cannabis: Potenzial und Risiko. Eine wissenschaftliche Bestandsaufnahme. Springer Nature, HeidelbergCrossRef
35.
36.
Hoch E, Zimmermann P, Henker J, Rohrbacher H, Noack R, Bühringer G, Wittchen H‑U (2011) Modulare Therapie von Cannabisstörungen. Das CANDIS-Programm. Hogrefe, Göttingen
37.
Izquierdo A (2017) Functional heterogeneity within rat orbitofrontal cortex in reward learning and decision making. J Neurosci 37:10529–10540PubMedPubMedCentralCrossRef
38.
Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin HJ, Lançon C (2014) Acute and long-term effects of cannabis use: a review. CPD 20(25):4112–4118CrossRef
39.
Kober H, DeVito EE, DeLeone CM et al (2014) Cannabis abstinence during treatment and one-year follow-up: relationship to neural activity in men. Neuropsychopharmacology 39:2288–2298PubMedPubMedCentralCrossRef
40.
Koenders L, Cousijn J, Vingerhoets WA et al (2016) Grey matter changes associated with heavy cannabis use: a longitudinal sMRI study. PLoS ONE 11:e152482PubMedPubMedCentralCrossRef
41.
42.
43.
Mackey S, Allgaier N, Chaarani B et al (2019) Mega-analysis of gray matter volume in substance dependence: general and substance-specific regional effects. Am J Psychiatry 176:119–128PubMedCrossRef
44.
Mak LE, Minuzzi L, MacQueen G et al (2017) The default mode network in healthy individuals: a systematic review and meta-analysis. Brain Connec 7:25–33CrossRef
45.
46.
47.
Medina KL, Nagel BJ, Tapert SF (2010) Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiatry Res 182:152–159PubMedPubMedCentralCrossRef
48.
Nader DA, Sanchez ZM et al (2018) Effects of regular cannabis use on neurocognition, brain structure, and function: a systematic review of findings in adults. Am J Drug Alcohol Abuse 44:4–18PubMedCrossRef
49.
National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, & Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda (2017) The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press, US
50.
Orth B, Merkel C (2022) Der Substanzkonsum Jugendlicher und junger Erwachsener in Deutschland. Ergebnisse des Alkoholsurveys 2021 zu Alkohol, Rauchen, Cannabis und Trends. BZgA-Forschungsbericht. Bundeszentrale für gesundheitliche Aufklärung, Köln
51.
52.
Pagliaccio D, Barch DM, Bogdan R et al (2015) Shared predisposition in the association between cannabis use and subcortical brain structure. JAMA Psychiatry 72:994–1001PubMedPubMedCentralCrossRef
53.
Pujol J, Blanco-Hinojo L, Batalla A et al (2014) Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J Psychiatr Res 51:68–78PubMedCrossRef
54.
Rauschert C, Möckl J, Seitz NN et al (2022) The Use of Psychoactive Substances in Germany. Dtsch Ärztebl Int 119:527–534PubMedPubMedCentral
55.
Renard J, Rosen LG, Loureiro M et al (2017) Adolescent cannabinoid exposure induces a persistent sub-cortical hyper-dopaminergic state and associated molecular adaptations in the prefrontal cortex. Cereb Cortex 27:1297–1310PubMed
56.
Renard J, Krebs MO, Le Pen G et al (2014) Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Front Neurosci 8:361PubMedPubMedCentralCrossRef
57.
Roser P (2019) Cannabis und Schizophrenie – Risikofaktoren, diagnostische Einordnung und Auswirkungen auf Verlauf und Prognose. Forens Psychiatr Psychol Kriminol 13:225–232CrossRef
58.
Rubino T, Prini P, Piscitelli F et al (2015) Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiol Dis 73:60–69PubMedCrossRef
59.
Rubino T, Vigano’ D, Realini N et al (2008) Chronic delta 9‑tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33:2760–2771PubMedCrossRef
60.
Kruse LC, Cao JK, Viray K et al (2019) Voluntary oral consumption of Delta(9)-tetrahydrocannabinol by adolescent rats impairs reward-predictive cue behaviors in adulthood. Neuropsychopharmacology 44:1406–1414PubMedPubMedCentralCrossRef
61.
Rubino T, Zamberletti E, Parolaro D (2012) Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol 26:177–188PubMedCrossRef
62.
Saß H, Wittchen HU, Zaudig M, Houben I (1998) Diagnostische Kriterien DSM-IV. Hogrefe, Göttingen
63.
64.
65.
Soyka M, Preuss U, Hoch E (2017) Cannabisinduzierte Störungen. Nervenarzt 88:311–325PubMedCrossRef
66.
67.
Weaver IC (2014) Integrating early life experience, gene expression, brain development, and emergent phenotypes: unraveling the thread of nature via nurture. Adv Genet 86:277–307PubMedCrossRef
68.
Wesley MJ, Lile JA, Hanlon CA et al (2016) Abnormal medial prefrontal cortex activity in heavy cannabis users during conscious emotional evaluation. Psychopharmacology 233:1035–1044 (Berl)PubMedCrossRef
69.
Wetherill RR, Fang Z, Jagannathan K et al (2015) Cannabis, cigarettes, and their co-occurring use: Disentangling differences in default mode network functional connectivity. Drug Alcohol Depend 153:116–123PubMedPubMedCentralCrossRef
70.
Wollman SC, Alhassoon OM, Hall MG et al (2017) Gray matter abnormalities in opioid-dependent patients: A neuroimaging meta-analysis. Am J Drug Alcohol Abuse 43:505–517PubMedCrossRef
71.
Zahr NM, Pfefferbaum A (2017) Alcohol’s effects on the brain: neuroimaging results in humans and animal models. Alcohol Res 38:183–206PubMedPubMedCentral
72.
Zimmermann K, Yao S, Heinz M et al (2018) Altered orbitofrontal activity and dorsal striatal connectivity during emotion processing in dependent marijuana users after 28 days of abstinence. Psychopharmacology 235:849–859PubMedCrossRef
73.
Zurolo E, Iyer AM, Spliet WG et al (2010) CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies. Neuroscience 170:28–41PubMedCrossRef
74.
Aizpurua-Olaizola O, Soydaner U, Ozturk E et al (2016) Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. J Nat Prod 79:324–331PubMedCrossRef
75.
Allsop DJ, Copeland J, Lintzeris N et al (2014) Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiat 71:281–291CrossRef
76.
Andries A, Frystyk J, Flyvbjerg A et al (2014) Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord 47:18–23PubMedCrossRef
77.
Aragona M, Onesti E, Tomassini V et al (2009) Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol 32:41–47PubMedCrossRef
78.
79.
Ball S, Vickery J, Hobart J et al (2015) The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomized double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Assess 19:vii–viiiPubMedPubMedCentralCrossRef
80.
Baron EP (2018) Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache 58:1139–1186PubMedCrossRef
81.
Batool S, Raza H, Zaidi J et al (2019) Synapse formation: from cellular and molecular mechanisms to neurodevelopmental and neurodegenerative disorders. J Neurophysiol 121:1381–1397PubMedCrossRef
82.
Amar BM (2006) Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105:1–25PubMedCrossRef
83.
Bergamaschi MM, Queiroz RHC, Chagas MHN et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36:1219–1226PubMedPubMedCentralCrossRef
84.
Berman JS, Symonds C, Birch R (2004) Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 112:299–306PubMedCrossRef
85.
Bilbao A, Spanagel R (2022) Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med 20:259–288PubMedPubMedCentralCrossRef
86.
87.
Blake DR, Robson P, Ho M et al (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatol 45(1):50–52CrossRef
88.
Boggs DL, Surti T, Gupta A et al (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo-controlled trial. Psychopharmacology 235:1923–1932PubMedCrossRef
89.
90.
Budney AJ, Vandrey RG, Hughes JR et al (2007) Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86:22–29PubMedCrossRef
91.
Carley DW, Prasad B, Reid KJ et al (2018) Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: Effects of dronabinol in obstructive sleep apnea. Sleep 41(1):184CrossRef
92.
Cascio MG, Gauson LA, Stevenson LA et al (2010) Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159:129–141PubMedCrossRef
93.
Cascio MG, Zamberletti E, Marini P et al (2015) The phytocannabinoid, delta(9)-tetrahydrocannabivarin, can act through 5‑HT(1)A receptors to produce antipsychotic effects. Br J Pharmacol 172:1305–1318PubMedPubMedCentralCrossRef
94.
95.
Colizzi M, McGuire P, Pertwee RG et al (2016) Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosc Biobehav Rev 64:359–381CrossRef
96.
Collin C, Ehler E, Waberzinek G et al (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32:451–459PubMedCrossRef
97.
Cooper RE, Williams E, Seegobin S et al (2017) Cannabinoids in attention-deficit/hyperactivity disorder: a randomized controlled trial. Eur Neuropsychopharmacol 27:795–808PubMedCrossRef
98.
Crippa JAS, Derenusson GN, Ferrari TB (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 25:121–130PubMedCrossRef
99.
D’Souza DC, Abi-Saab WM, Madonick S et al (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608PubMedCrossRef
100.
D’Souza DC, Cortes-Briones J, Creatura G et al (2019) Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomized controlled trial. Lancet Psychiatry 6:35–45PubMedCrossRef
101.
De Almeida CMO, Brito MMC, Bosaipo NB et al (2021) Cannabidiol for rapid eye movement sleep behavior disorder. Mov Disord 36:1711–1715PubMedCrossRef
102.
De Faria SM, de Morais FD, Tumas V et al (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. J Psychopharmacol 34:189–196PubMedCrossRef
103.
Devinsky O, Cross JH, Laux L et al (2017) Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med 376:2011–2020PubMedCrossRef
104.
Devinsky O, Patel AD, Cross JH et al (2018) Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med 378:1888–1897PubMedCrossRef
105.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015) Treatment of cannabis-related disorders in Europe. EMCDDA Insight Report. European Monitoring Centre for Drugs and Drug Addiction, Lisbon
106.
Fairhurst C, Kumar R, Checketts D et al (2020) Efficacy and safety of Nabiximols cannabinoid medicine for pediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Dev Med Child Neurol 62:1031–1039PubMedCrossRef
107.
Fallon MT, Albert Lux E, McQuade R et al (2017) Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain 11:119–133PubMedPubMedCentralCrossRef
108.
Frank B, Serpell MG, Hughes J et al (2008) Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 336:199–201PubMedPubMedCentralCrossRef
109.
Freeman TP, Hindocha C, Baio G et al (2020) Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomized, adaptive Bayesian trial. Lancet Psychiatry 7:865–874PubMedPubMedCentralCrossRef
110.
Giese MW, Lewis MA, Giese L et al (2015) Development and validation of a reliable and robust method for the analysis of cannabinoids and terpenes in cannabis. J Aoac Int 98:1503–1522PubMedCrossRef
111.
Glass RM, Uhlenhuth EH, Hartel FW et al (1981) Single-dose study of nabilone in anxious volunteers. J Clin Pharmacol 21:383S–396SPubMedCrossRef
112.
Gould J (2015) 4 Big Questions. Nat Outlook 525:S18
113.
Gross H, Ebert MH, Faden VB et al (1983) A double-blind trial of delta 9‑tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol 3:165–171PubMedCrossRef
114.
Grotenhermen F, Berger M, Gebhardt K (2015) Cannabidiol. Nachtschatten Verlag, Solothurn
115.
116.
Haney M, Cooper ZD, Bedi G et al (2013) Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38:1557–1565PubMedPubMedCentralCrossRef
117.
Haney M, Hart CL, Vosburg SK et al (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29:158–170PubMedCrossRef
118.
Häuser W, Petzke F et al (2020) Welche Cannabis-basierten Arzneimittel gibt es? MMW. Fortschr Med 162:6–9CrossRef
119.
Herrmann ES, Cooper ZD, Bedi G et al (2016) Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology 233:2469–2478PubMedPubMedCentralCrossRef
120.
Herrmann ES, Cooper ZD, Bedi G et al (2019) Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. Addict Biol 24:765–776PubMedCrossRef
121.
Herrmann N, Ruthirakuhan M, Gallagher D et al (2019) Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease. Am J Geriatr Psychiatry 27:1161–1173PubMedCrossRef
122.
123.
Hill KP, Palastro MD, Gruber SA et al (2017) Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study. Am J Addict 26:795–801PubMedPubMedCentralCrossRef
124.
Hoch E, Hämming PUW (2024) Suchtmedizin. In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg) Cannabis und Cannabinoide, 2. Aufl. Urban & Fischer Elsevier. im Druck, München
125.
Hollister LE, Gillespie HK, Ohlsson A et al (1981) Do plasma concentrations of ∆9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 21(S1):171S–177SPubMedCrossRef
126.
Hurd YL, Spriggs S, Alishayev J et al (2019) Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 176:911–922PubMedCrossRef
127.
Jadoon KA, Ratclife SH, Barrett DA et al (2016) Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care 39:1777–1786PubMedCrossRef
128.
Jetly R, Heber A, Fraser G et al (2015) The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585–588PubMedCrossRef
129.
Johnson JR, Burnell-Nugent M, Lossignol D et al (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39:167–179PubMedCrossRef
130.
Kathmann M, Flau K, Redmer A et al (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 2006(372):354–361CrossRef
131.
Langford RM, Mares J, Novotna A et al (2013) A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260:984–997PubMedCrossRef
132.
Leocani L, Nuara A, Houdayer E et al (2015) Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol 262:2520–2527PubMedCrossRef
133.
Levin FR, Mariani JJ, Brooks DJ et al (2011) Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116:142–150PubMedPubMedCentralCrossRef
134.
Levin FR, Mariani JJ, Pavlicova M et al (2016) Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebocontrolled trial. Drug Alcohol Depend 159:53–60PubMedCrossRef
135.
Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2(3):e94PubMedPubMedCentralCrossRef
136.
Lichtman AH, Lux EA, McQuade R et al (2018) Results of a double-blind, randomized, placebo-controlled study of Nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 55(2):179–188PubMedCrossRef
137.
Lintzeris N, Bhardwaj A, Mills L et al (2019) Nabiximols for the treatment of cannabis dependence: a randomized clinical trial. JAMA Intern Med 179:1242–1253PubMedPubMedCentralCrossRef
138.
López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P et al (2016) A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J Neurol 263:1390–1400PubMedCrossRef
139.
Malik Z, Bayman L, Valestin J et al (2017) Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial. Dis Esophagus J Int Soc Dis Esophagus 30:1–8
140.
Marcu JP (2016) An overview of major and minor phytocannabinoids. In: Preedy VR (Hrsg) Neuropathology of Drug Addictions and Substance Misuse, Bd. 2016. Academic Press, London:, S 672–678CrossRef
141.
Markovà J, Essner U, Akmaz B et al (2019) Sativex(®) as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomized clinical trial. Int J Neurosci 129:119–128PubMedCrossRef
142.
143.
McGuire P, Robson P, Cubała W et al (2018) A randomized controlled trial of cannabidiol in schizophrenia. Schizophr Bull 2018(44):27CrossRef
144.
Meneses-Gaya C, Crippa JA, Hallak JE et al (2021) Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. Rev Bras Psiquiatr 43:467–476PubMedCrossRef
145.
Miller I, Schefer IE, Gunning B et al (2020) Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol 77:613–621PubMedCrossRef
146.
Morgan CJA, Das RK, Joye A et al (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38:2433–2436PubMedCrossRef
147.
Müller-Vahl KR, Koblenz A, Jöbges M et al (2001) Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 34:19–24PubMedCrossRef
148.
Müller-Vahl KR, Pisarenko A, Szejko N et al (2023) CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders—Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. Psychiatry Res 323:115135PubMedCrossRef
149.
Müller-Vahl KR, Schneider U, Koblenz A et al (2002) Treatment of Tourette’s syndrome with Delta 9‑tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57–61PubMedCrossRef
150.
Müller-Vahl KR, Schneider U, Prevedel H et al (2003) Delta 9‑tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459–465PubMedCrossRef
151.
Narang S, Gibson D, Wasan AD et al (2008) Efcacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 9:254–264PubMedCrossRef
152.
153.
Notcutt W, Langford R, Davies P et al (2012) A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex®(Nabiximols). Mult Scler 18:219–228PubMedCrossRef
154.
Novotna A, Mares J, Ratclife S et al (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of Nabiximols* Sativex(®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18:1122–1131PubMedCrossRef
155.
Nurmikko TJ, Serpell MG, Hoggart B et al (2007) Sativex successfully treats neuropathic pain characterized by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain 133:210–220PubMedCrossRef
156.
O’Neill A, Wilson R, Blest-Hopley G et al (2021) Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med 51:596–606PubMedCrossRef
157.
Peball M, Krismer F, Knaus H‑G et al (2020) Non-motor symptoms in Parkinson’s disease are reduced by nabilone. Ann Neurol 88:712–722PubMedPubMedCentralCrossRef
158.
Pietsch B, Arnaud N, Lochbühler K, Rossa M, Kraus L, Gomes de Matos E, Grahlher K, Thomasius R, Hanewinkel R, Morgenstern M (2023) Effects of an App-Based Intervention Program to Reduce Substance Use, Gambling, and Digital Media Use in Adolescents and Young Adults: A Multicenter, Cluster-Randomized Controlled Trial in Vocational Schools in Germany. Int J Environ Res Public Health 20(3):1970PubMedPubMedCentralCrossRef
159.
160.
Pini LA, Guerzoni S, Cainazzo MM et al (2012) Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain 13:677–684PubMedPubMedCentralCrossRef
161.
Portenoy RK, Ganae-Motan ED, Allende S et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13:438–449PubMedCrossRef
162.
Preuss UW, Hoch E (2021) Im Spannungsfeld: Cannabinoide: Riskantes Rauschmittel und Arznei gegen psychische. Störungen Dnp – Neurol Psychiater 22:40–48CrossRef
163.
Preuss UW, Hoch E, Wong JWM, Pogarell O (2018) Medizinisches Cannabis: Hintergründe, Evidenzen, Praxishinweise. Suchtmed 20:349–367
164.
Preuss UW, Watzke AB, Zimmermann J et al (2010) Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. Drug Alcohol Depend 106:133–141PubMedCrossRef
165.
Rabinak CA, Blanchette A, Zabik NL et al (2020) Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study. Psychopharmacology 237:1813–1826PubMedPubMedCentralCrossRef
166.
Riva N, Mora G, Sorarù G et al (2019) Safety and efficacy of Nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomized, placebo-controlled, phase 2 trial. Lancet Neurol 18:155–164PubMedCrossRef
167.
Rog DJ, Nurmikko TJ, Friede T et al (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65:812–819PubMedCrossRef
168.
Rømer Thomsen K, Thylstrup B, Kenyon EA et al (2022) Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth? Neurosci Biobehav Rev 132:169–180PubMedCrossRef
169.
Serpell M, Ratclife S, Hovorka J et al (2014) A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain 18:999–1012PubMedCrossRef
170.
Skrabek RQ, Galimova L, Ethans K et al (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9:164–173PubMedCrossRef
171.
Solowij N, Broyd SJ, Beale C et al (2018) Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial. Cannabis Cannabinoid Res 3:21–34PubMedPubMedCentralCrossRef
172.
Thiele EA, Bebin EM, Bhathal H et al (2021) Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol 78:285–292PubMedCrossRef
173.
Toth C, Mawani S, Brady S et al (2012) An enriched enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 153:2073–2082PubMedCrossRef
174.
Trigo JM, Lagzdins D, Rehm J et al (2016) Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend 161:298–306PubMedPubMedCentralCrossRef
175.
Trigo JM, Soliman A, Quilty LC et al (2018) Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS ONE 13:e190768PubMedPubMedCentralCrossRef
176.
Turcott JG, Del Rocío-Guillen-Núñez M, Flores-Estrada D et al (2018) The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support care cancer. J Multinatl Assoc Support Care Cancer 26:3029–3830CrossRef
177.
Ungerleider JT, Andrysiak T, Fairbanks L et al (1982) Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 50:636–645PubMedCrossRef
178.
van Amerongen G, Kanhai K, Baakman AC et al (2018) Effects on spasticity and neuropathic pain of an oral formulation of ∆9-tetrahydrocannabinol in patients with progressive multiple sclerosis. Clin Ther 240:1467–1482CrossRef
179.
van den Elsen GAH, Ahmed AIA, Verkes R‑J et al (2015) Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology 84:2338–2346PubMedPubMedCentralCrossRef
180.
Vandrey R, Stitzer ML, Mintzer MZ et al (2013) The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 128:64–70PubMedCrossRef
181.
Vaney C, Heinzel-Gutenbrunner M, Jobin P et al (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10:417–424PubMedCrossRef
182.
Vela J, Dreyer L, Petersen K et al (2022) Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind placebo-controlled trial. Pain 163:1206–1214PubMedCrossRef
183.
Verhoeckx KC, Korthout HA, van Meeteren-Kreikamp AP et al (2006) Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 6:656–665PubMedCrossRef
184.
Volicer L, Stelly M, Morris J et al (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatric Psychiatr 12:913–919CrossRef
185.
Wade DT, Makela P, Robson P et al (2004) Do cannabis-based medicinal extracts have general or specifc effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434–441PubMedCrossRef
186.
Ware MA, Fitzcharles M‑A, Joseph L et al (2010) The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 110:604–610PubMedCrossRef
187.
Weber M, Goldman B, Truniger S (2010) Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomized, double-blind crossover trial. J Neurol Neurosurg Psychiatry 81:1135–1140PubMedCrossRef
188.
Zajicek J, Fox P, Sanders H et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 362:1517–1526PubMedCrossRef
Metadaten
Titel
Cannabiskonsum und Cannabiskonsumstörungen
verfasst von
Prof. Dr. E. Hoch
Prof. Dr. med. U. W. Preuss
Publikationsdatum
12.08.2024
Verlag
Springer Medizin
Erschienen in
Der Nervenarzt / Ausgabe 9/2024
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-024-01722-5

Weitere Artikel der Ausgabe 9/2024

Mitteilungen der DGPPN 09/2024

  • Mitteilungen der DGPPN

Psychiatrische Therapie mit Psychedelika und Dissoziativa: Was ist zu beachten?

Synthetische Drogen - Herausforderungen für die psychiatrische Versorgung

Individual Placement and Support in der psychiatrischen Versorgung: Evaluation klinischer Routinedaten mittels eines retrospektiven Chart-Reviews

Kratom – vom natürlichen Heilmittel zur Suchtdroge und zurück

Familienzentrierte Behandlungsansätze für drogenabhängige Eltern

Neu im Fachgebiet Psychiatrie

MCI-Screening per Handy und Smartwatch? Könnte klappen

Handys und Smartwatches könnten niedrigschwellige Tools sein, um eine beginnende Demenz zu erfassen. In einer US-Studie ließ sich damit eine leichte kognitive Beeinträchtigung (MCI) gut nachweisen. Auch waren gerade die älteren Teilnehmenden sehr motiviert.

Demenz-Leitlinie aktualisiert

  • 13.03.2025
  • Demenz
  • Nachrichten

Empfohlen wird jetzt auch eine Musiktherapie sowie bei unklarem diagnostischem Befund ein Tau-PET, und Depressive mit leichten kognitiven Störungen sollten eine Verhaltenstherapie erhalten – das sind einige wichtige Änderungen der aktuellen S3-Leitlinie Demenzen.

Positive Signale für Semaglutid bei Alkoholabhängigkeit

Daten einer kleinen Phase-II-Studie sprechen dafür, GLP-1-Rezeptoragonisten in der Behandlung von Alkoholabhängigkeit weiter zu untersuchen.

Wer hat Angst vorm elektromagnetischen Feld?

Ist elektromagnetische Strahlung auch unterhalb von gesetzlichen Grenzwerten gesundheitsschädlich? Ein kleiner Teil der Ärzteschaft hält das für möglich, wobei eher an psychosomatische Effekte gedacht wird, wie eine deutsche Studie nahelegt. Das selbst eingeschätzte Wissen zum Thema ist indes gering.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise